Indoco Remedies Q2FY26 – From FDA Frown to Facelift: The Pharma Underdog’s Audited Reality Show
1. At a Glance
Mumbai-based Indoco Remedies Ltd just dropped its Q2FY26 results, and boy, it’s not a script from Pharma Made Easy — it’s more like Breaking Bad Meets Audit Report. Revenue for the quarter stood at ₹4,293 million (₹429.3 crore), up 12% YoY, but the company managed to post yet another consolidated loss of ₹9.21 crore. Yes, your favourite CYCLOPAM-maker is in pain itself.
The market cap currently lounges around ₹2,419 crore, with a share price of ₹264 — roughly 25% down from its 52-week high of ₹355. With a P/E “not meaningful” (because losses, duh), an EV/EBITDA of 44x, and a Debt/Equity ratio of 1.02, Indoco looks like a student who spent too much on lab experiments and not enough on grades.
ROE and ROCE? Both negative. Dividend yield? A teasing 0.08%, or what you might call “the financial equivalent of a breath mint.” And while the company got some FDA approvals this quarter (good news), its auditors waved a yellow flag, citing “subsidiaries with negative net worth” (not-so-good news).
Still, as they say in Bollywood, picture abhi baaki hai mere dost. Let’s dive into Indoco’s spicy script — equal parts ambition, audit, and aspirin.
2. Introduction
If the Indian pharma industry were a cricket match, Indoco Remedies would be that seasoned middle-order batsman who occasionally smashes a six, but mostly gets caught at midwicket.
Founded decades ago and headquartered in Mumbai, Indoco has long positioned itself as a serious contender in both domestic and international formulations. But in FY25 and FY26, it found itself juggling between USFDA letters, plant refurbishments, and the joyless math of negative profits.
Q2FY26 was an especially “head-scratching” quarter. On one hand, sales growth was strong, approvals were coming through — Rivaroxaban, Allopurinol, Varenicline, Cetirizine — you name it. On the other, its profit line behaved like a soap bubble at a birthday party: there, shimmering… and pop! gone.
But hey, they did fix their USFDA issues at the Patalganga API facility with zero Form 483 observations. That’s like passing a surprise school inspection with full marks after years of “needs improvement.”
Indoco is an interesting story: a company that makes medicines for pain and stress, while clearly living both in its balance sheet.
3. Business Model – WTF Do They Even Do?
At its core, Indoco Remedies makes and markets pharmaceutical formulations and APIs (Active Pharmaceutical Ingredients). Think of it as the chef who not only cooks the dish (formulations) but also grows the key ingredients (APIs).
Its business is divided into three segments:
Domestic Formulations (48% of FY24 revenue): The local hero segment. Indoco ranks 31st in India with over 106 million prescriptions annually and 45 products in the top five of their respective therapeutic areas. The brand stars?
Cyclopam – the undisputed boss of stomach cramps.
Sensodent-K – India’s tooth sensitivity saviour.
Karvol Plus – the minty superhero for your clogged nose.
Export Formulations (43%): Indoco ships its magic pills to over 55 countries, including the US, UK, Germany, and Africa. Europe contributes the lion’s share (49%), followed by North America (32%) and Emerging Markets (19%). The US business faced turbulence after FDA warnings but is slowly being reanimated — like a pharma zombie movie where compliance is the cure.
API & CRO (9%): Indoco’s API business manufactures anti-diabetic, anti-gout, and ophthalmic APIs. Its AnaCipher CRO in Hyderabad conducts bioequivalence and pharmacovigilance studies. Translation: they test whether a generic pill behaves like the original one and ensure no patient suddenly grows a tail.
In short: Indoco’s model is a classic “make drugs, sell drugs, test drugs” model — but lately, it’s been more “fix plants, reply to auditors, calm shareholders.”
4. Financials Overview
Quarterly Snapshot (₹ in Crores)
Metric
Q2FY26
Q2FY25
Q1FY26
YoY %
QoQ %
Revenue
484.67
432.66
439.67
12.0%
10.2%
EBITDA
43.05
40.25
17.53
6.9%
145.7%
PAT
-9.21
-10.01
-36.35
-7.9%
74.7%
EPS (₹)
-0.86
-1.04
-3.88
—
—
Commentary: Revenue growth? Decent. EBITDA? Recovering. Profit? Missing, presumed dead. But the loss narrowed sharply QoQ, showing that Indoco’s painkillers may finally be working — on itself.
EBITDA margins jumped to 8.9% this quarter, a dramatic comeback from 4% in Q1FY26, thanks to cost optimization and lesser production inefficiencies post USFDA fixes.
Still, P/E is “not meaningful” because — well — no E.
One Response
Nice and Funny analysis